Inhibition of PKCε in this context is not a direct attack on the drivers of disease but instead targets a tumour-specific vulnerability, resulting in a synthetic lethal outcome, as a function of the G2 arrest competence (discussed [52]). Here, PRKCE is linked to neoplasm.